文献速递乳腺癌放疗

术后放疗对65岁以下雌激素受体阳性管状乳腺癌患者生存结局的影响

The effects of postoperative radiotherapy on survival outcomes in patients under 65 with estrogen receptor positive tubular breast carcinoma.
PubMed 文献 · Radiat Oncol · 2018-11-20

基于监测、流行病学和最终结果(SEER)数据库2000至2013年接受保乳手术的雌激素受体阳性T1N0M0管状乳腺癌且年龄小于65岁的患者数据,分析2442例患者,其中2020例(82.7%)接受术后放疗、422例(17.3%)未接受。多因素Cox分析显示术后放疗与更好的乳腺癌特异性生存(BCSS)(HR 0.297,95%CI 0.105-0.836,p=0.022)和总生存(OS)(HR 0.656,95%CI 0.441-0.978,p=0.038)显著相关。结论认为术后放疗改善年龄<50岁患者的生存结局,而年龄≥50岁患者省略术后放疗可能不降低生存。

要点

  • 2442例患者中2020例(82.7%)接受术后放疗,422例(17.3%)未接受,研究期间接受与未接受放疗的患者数无差异(p=0.184)。
  • 多因素Cox分析显示术后放疗与更好的BCSS(HR 0.297,95%CI 0.105-0.836,p=0.022)和OS(HR 0.656,95%CI 0.441-0.978,p=0.038)显著相关。
  • 术后放疗在年龄<50岁、非西班牙裔白人、高分化肿瘤和孕激素受体阳性肿瘤亚组中提高BCSS和OS。

核心结论

  • 保乳手术后术后放疗改善了年龄<50岁管状乳腺癌患者的生存结局。
  • 年龄≥50岁患者省略术后放疗可能不降低生存。

研究设计与样本

  • 回顾性分析监测、流行病学和最终结果(SEER)数据库2000至2013年接受保乳手术的雌激素受体阳性T1N0M0管状乳腺癌且年龄小于65岁的患者数据。
  • 共分析2442例患者,其中2020例(82.7%)接受术后放疗,422例(17.3%)未接受。

主要发现

  • 研究期间接受与未接受术后放疗的患者数无差异(p=0.184)。
  • 高分化肿瘤患者更可能接受放疗。
  • 多因素Cox分析显示术后放疗与更好的乳腺癌特异性生存(BCSS)显著相关(HR 0.297,95%CI 0.105-0.836,p=0.022)。
  • 多因素Cox分析显示术后放疗与更好的总生存(OS)显著相关(HR 0.656,95%CI 0.441-0.978,p=0.038)。
  • 接受术后放疗者10年BCSS为99.3%,未接受者为98.1%(p=0.020);10年OS分别为93.4%和91.0%(p=0.029)。

关键数值与推荐

  • 术后放疗在年龄<50岁、非西班牙裔白人、高分化肿瘤和孕激素受体阳性肿瘤亚组中提高BCSS和OS。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The value of postoperative radiotherapy in tubular breast carcinoma patients under 65 years is uncertain. METHODS: Data on patients with estrogen receptor positive T1N0M0 tubular breast carcinoma who were younger than 65 years and who received breast-conserving surgery between 2000 and 2013 were retrieved from the Surveillance, Epidemiology and End Results database. Demographic, clinicopathologic features, and receipt of postoperative radiotherapy were analyzed to investigate effects on survival. RESULTS: Data from 2442 patients were analyzed, of whom 2020 (82.7%) received postoperative radiotherapy and 422 (17.3%) did not. The number of patients treated with or without postoperative radiotherapy showed no differences during the study period (p = 0.184). Radiotherapy was more likely to be administered in patients with well differentiated tumors. Multivariate Cox analysis showed that postoperative radiotherapy delivery was significantly correlated with better breast cancer-specific survival (BCSS) (hazard ratio [HR] 0.297, 95% confidence interval [CI] 0.105-0.836, p = 0.022) and overall survival (OS) (HR 0.656, 95% CI 0.441-0.978, p = 0.038). Ten 10-year BCSS was 99.3% in patients who received postoperative radiotherapy and 98.1% in those who did not (p = 0.020), and 10-year OS was 93.4 and 91.0%, respectively (p = 0.029). Postoperative radiotherapy increased BCSS and OS in the subgroups of age < 50 years, non-Hispanic white, well differentiated tumors, and progesterone receptor positive tumors. CONCLUSIONS: Postoperative radiotherapy after breast-conserving surgery improved survival outcomes in tubular breast carcinoma patients aged < 50 years. However, omitting postoperative radiotherapy may not decrease survival in patients aged ≥50 years.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen JX, Zhang WW, Dong Y, et al. The effects of postoperative radiotherapy on survival outcomes in patients under 65 with estrogen receptor positive tubular breast carcinoma. Radiat Oncol. 2018. PMID: 30458816. doi:10.1186/s13014-018-1177-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。